Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 5.08 percent. This is a 62.67 percent increase over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $7.543 million which beat the analyst consensus estimate of $5.020 million by 50.26 percent. This is a 12.27K percent increase over sales of $61.000 thousand the same period last year.